A unifying approach for surrogate marker validation based on Prentice's criteria

Part of the recent literature on the evaluation of surrogate endpoints starts from a multi‐trial approach which leads to a definition of validity in terms of the quality of both trial‐level and individual‐level association between a potential surrogate and a true endpoint, Buyse et al. These authors...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Statistics in medicine 2006-01, Vol.25 (2), p.205-221
Hauptverfasser: Alonso, Ariel, Molenberghs, Geert, Geys, Helena, Buyse, Marc, Vangeneugden, Tony
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 221
container_issue 2
container_start_page 205
container_title Statistics in medicine
container_volume 25
creator Alonso, Ariel
Molenberghs, Geert
Geys, Helena
Buyse, Marc
Vangeneugden, Tony
description Part of the recent literature on the evaluation of surrogate endpoints starts from a multi‐trial approach which leads to a definition of validity in terms of the quality of both trial‐level and individual‐level association between a potential surrogate and a true endpoint, Buyse et al. These authors proposed their methodology based on the simplest cross‐sectional case in which both the surrogate and the true endpoint are continuous and normally distributed. Different variations to this theme have been implemented for binary responses, times to event, combinations of binary and continuous endpoints, etc. However, a drawback of this methodology is that different settings have led to different definitions to quantify the association at the individual‐level. In the longitudinal setting; Alonso et al. defined a class of canonical correlation functions that can be used to study surrogacy at the trial and individual‐level. In the present work, we propose a new approach to evaluate surrogacy in the repeated measurements framework, we also show the connection between this proposal and the previous ones reported in the literature. Finally, we extend this concept to the non‐normal case using the so‐called ‘likelihood reduction factor’ (LRF) a new validation measure based on some of the Prentice's criteria. We apply the previous methodology using data from two clinical studies in psychiatry and ophthalmology. Copyright © 2005 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/sim.2315
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67605035</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>972308431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4505-76588d4233f6e703ad03671ffb077d7c286f5d571554ed082ae069b59a21323d3</originalsourceid><addsrcrecordid>eNp1kEtP3DAUha0KVAZaiV-ALBbQTei1HdvJckRbQBoeEo-yszzxDTXNJIOdtJ1_X6OJQEJide_i09E5HyG7DI4YAP8a_eKICyY_kAmDUmfAZbFBJsC1zpRmcotsx_gIwJjk-iPZYopzyEs9IVdTOrS-Xvn2gdrlMnS2-kXrLtA4hNA92B7pwobfGOgf23hne9-1dG4jOpqeq4Bt7ys8jLQKvsfg7SeyWdsm4ufx7pDbH99vjk-z2eXJ2fF0llW5BJlpJYvC5VyIWqEGYR2I1LSu56C10xUvVC2dTN1ljg4KbhFUOZel5Uxw4cQOOVjnps5PA8beLHyssGlsi90QjdIKJAiZwP034GM3hDZ1Mzw5y0GIMkFf1lAVuhgD1mYZfBq-MgzMs2KTFJtnxQndG_OG-QLdKzg6TUC2Bv76BlfvBpnrs_MxcOR97PHfC5-spxFCS_Pz4sR8uyvuFLufmWvxH4K7knE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223140339</pqid></control><display><type>article</type><title>A unifying approach for surrogate marker validation based on Prentice's criteria</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Alonso, Ariel ; Molenberghs, Geert ; Geys, Helena ; Buyse, Marc ; Vangeneugden, Tony</creator><creatorcontrib>Alonso, Ariel ; Molenberghs, Geert ; Geys, Helena ; Buyse, Marc ; Vangeneugden, Tony</creatorcontrib><description>Part of the recent literature on the evaluation of surrogate endpoints starts from a multi‐trial approach which leads to a definition of validity in terms of the quality of both trial‐level and individual‐level association between a potential surrogate and a true endpoint, Buyse et al. These authors proposed their methodology based on the simplest cross‐sectional case in which both the surrogate and the true endpoint are continuous and normally distributed. Different variations to this theme have been implemented for binary responses, times to event, combinations of binary and continuous endpoints, etc. However, a drawback of this methodology is that different settings have led to different definitions to quantify the association at the individual‐level. In the longitudinal setting; Alonso et al. defined a class of canonical correlation functions that can be used to study surrogacy at the trial and individual‐level. In the present work, we propose a new approach to evaluate surrogacy in the repeated measurements framework, we also show the connection between this proposal and the previous ones reported in the literature. Finally, we extend this concept to the non‐normal case using the so‐called ‘likelihood reduction factor’ (LRF) a new validation measure based on some of the Prentice's criteria. We apply the previous methodology using data from two clinical studies in psychiatry and ophthalmology. Copyright © 2005 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0277-6715</identifier><identifier>EISSN: 1097-0258</identifier><identifier>DOI: 10.1002/sim.2315</identifier><identifier>PMID: 16220497</identifier><identifier>CODEN: SMEDDA</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Antipsychotic Agents - therapeutic use ; Biomarkers ; Clinical trials ; Correlation analysis ; Data Interpretation, Statistical ; hierarchical model ; Humans ; Interferon-alpha - therapeutic use ; likelihood reduction factor ; Longitudinal Studies ; Macular Degeneration - drug therapy ; Medical research ; Meta-Analysis as Topic ; Predictive Value of Tests ; Prentice criteria ; Randomized Controlled Trials as Topic - methods ; Reproducibility of Results ; Risperidone - therapeutic use ; Schizophrenia - drug therapy ; Statistical analysis ; surrogate endpoints ; Validation studies ; Visual Acuity - drug effects</subject><ispartof>Statistics in medicine, 2006-01, Vol.25 (2), p.205-221</ispartof><rights>Copyright © 2005 John Wiley &amp; Sons, Ltd.</rights><rights>Copyright (c) 2005 John Wiley &amp; Sons, Ltd.</rights><rights>Copyright John Wiley and Sons, Limited Jan 30, 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4505-76588d4233f6e703ad03671ffb077d7c286f5d571554ed082ae069b59a21323d3</citedby><cites>FETCH-LOGICAL-c4505-76588d4233f6e703ad03671ffb077d7c286f5d571554ed082ae069b59a21323d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fsim.2315$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fsim.2315$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16220497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alonso, Ariel</creatorcontrib><creatorcontrib>Molenberghs, Geert</creatorcontrib><creatorcontrib>Geys, Helena</creatorcontrib><creatorcontrib>Buyse, Marc</creatorcontrib><creatorcontrib>Vangeneugden, Tony</creatorcontrib><title>A unifying approach for surrogate marker validation based on Prentice's criteria</title><title>Statistics in medicine</title><addtitle>Statist. Med</addtitle><description>Part of the recent literature on the evaluation of surrogate endpoints starts from a multi‐trial approach which leads to a definition of validity in terms of the quality of both trial‐level and individual‐level association between a potential surrogate and a true endpoint, Buyse et al. These authors proposed their methodology based on the simplest cross‐sectional case in which both the surrogate and the true endpoint are continuous and normally distributed. Different variations to this theme have been implemented for binary responses, times to event, combinations of binary and continuous endpoints, etc. However, a drawback of this methodology is that different settings have led to different definitions to quantify the association at the individual‐level. In the longitudinal setting; Alonso et al. defined a class of canonical correlation functions that can be used to study surrogacy at the trial and individual‐level. In the present work, we propose a new approach to evaluate surrogacy in the repeated measurements framework, we also show the connection between this proposal and the previous ones reported in the literature. Finally, we extend this concept to the non‐normal case using the so‐called ‘likelihood reduction factor’ (LRF) a new validation measure based on some of the Prentice's criteria. We apply the previous methodology using data from two clinical studies in psychiatry and ophthalmology. Copyright © 2005 John Wiley &amp; Sons, Ltd.</description><subject>Antipsychotic Agents - therapeutic use</subject><subject>Biomarkers</subject><subject>Clinical trials</subject><subject>Correlation analysis</subject><subject>Data Interpretation, Statistical</subject><subject>hierarchical model</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>likelihood reduction factor</subject><subject>Longitudinal Studies</subject><subject>Macular Degeneration - drug therapy</subject><subject>Medical research</subject><subject>Meta-Analysis as Topic</subject><subject>Predictive Value of Tests</subject><subject>Prentice criteria</subject><subject>Randomized Controlled Trials as Topic - methods</subject><subject>Reproducibility of Results</subject><subject>Risperidone - therapeutic use</subject><subject>Schizophrenia - drug therapy</subject><subject>Statistical analysis</subject><subject>surrogate endpoints</subject><subject>Validation studies</subject><subject>Visual Acuity - drug effects</subject><issn>0277-6715</issn><issn>1097-0258</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtP3DAUha0KVAZaiV-ALBbQTei1HdvJckRbQBoeEo-yszzxDTXNJIOdtJ1_X6OJQEJide_i09E5HyG7DI4YAP8a_eKICyY_kAmDUmfAZbFBJsC1zpRmcotsx_gIwJjk-iPZYopzyEs9IVdTOrS-Xvn2gdrlMnS2-kXrLtA4hNA92B7pwobfGOgf23hne9-1dG4jOpqeq4Bt7ys8jLQKvsfg7SeyWdsm4ufx7pDbH99vjk-z2eXJ2fF0llW5BJlpJYvC5VyIWqEGYR2I1LSu56C10xUvVC2dTN1ljg4KbhFUOZel5Uxw4cQOOVjnps5PA8beLHyssGlsi90QjdIKJAiZwP034GM3hDZ1Mzw5y0GIMkFf1lAVuhgD1mYZfBq-MgzMs2KTFJtnxQndG_OG-QLdKzg6TUC2Bv76BlfvBpnrs_MxcOR97PHfC5-spxFCS_Pz4sR8uyvuFLufmWvxH4K7knE</recordid><startdate>20060130</startdate><enddate>20060130</enddate><creator>Alonso, Ariel</creator><creator>Molenberghs, Geert</creator><creator>Geys, Helena</creator><creator>Buyse, Marc</creator><creator>Vangeneugden, Tony</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20060130</creationdate><title>A unifying approach for surrogate marker validation based on Prentice's criteria</title><author>Alonso, Ariel ; Molenberghs, Geert ; Geys, Helena ; Buyse, Marc ; Vangeneugden, Tony</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4505-76588d4233f6e703ad03671ffb077d7c286f5d571554ed082ae069b59a21323d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antipsychotic Agents - therapeutic use</topic><topic>Biomarkers</topic><topic>Clinical trials</topic><topic>Correlation analysis</topic><topic>Data Interpretation, Statistical</topic><topic>hierarchical model</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>likelihood reduction factor</topic><topic>Longitudinal Studies</topic><topic>Macular Degeneration - drug therapy</topic><topic>Medical research</topic><topic>Meta-Analysis as Topic</topic><topic>Predictive Value of Tests</topic><topic>Prentice criteria</topic><topic>Randomized Controlled Trials as Topic - methods</topic><topic>Reproducibility of Results</topic><topic>Risperidone - therapeutic use</topic><topic>Schizophrenia - drug therapy</topic><topic>Statistical analysis</topic><topic>surrogate endpoints</topic><topic>Validation studies</topic><topic>Visual Acuity - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alonso, Ariel</creatorcontrib><creatorcontrib>Molenberghs, Geert</creatorcontrib><creatorcontrib>Geys, Helena</creatorcontrib><creatorcontrib>Buyse, Marc</creatorcontrib><creatorcontrib>Vangeneugden, Tony</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Statistics in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alonso, Ariel</au><au>Molenberghs, Geert</au><au>Geys, Helena</au><au>Buyse, Marc</au><au>Vangeneugden, Tony</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A unifying approach for surrogate marker validation based on Prentice's criteria</atitle><jtitle>Statistics in medicine</jtitle><addtitle>Statist. Med</addtitle><date>2006-01-30</date><risdate>2006</risdate><volume>25</volume><issue>2</issue><spage>205</spage><epage>221</epage><pages>205-221</pages><issn>0277-6715</issn><eissn>1097-0258</eissn><coden>SMEDDA</coden><abstract>Part of the recent literature on the evaluation of surrogate endpoints starts from a multi‐trial approach which leads to a definition of validity in terms of the quality of both trial‐level and individual‐level association between a potential surrogate and a true endpoint, Buyse et al. These authors proposed their methodology based on the simplest cross‐sectional case in which both the surrogate and the true endpoint are continuous and normally distributed. Different variations to this theme have been implemented for binary responses, times to event, combinations of binary and continuous endpoints, etc. However, a drawback of this methodology is that different settings have led to different definitions to quantify the association at the individual‐level. In the longitudinal setting; Alonso et al. defined a class of canonical correlation functions that can be used to study surrogacy at the trial and individual‐level. In the present work, we propose a new approach to evaluate surrogacy in the repeated measurements framework, we also show the connection between this proposal and the previous ones reported in the literature. Finally, we extend this concept to the non‐normal case using the so‐called ‘likelihood reduction factor’ (LRF) a new validation measure based on some of the Prentice's criteria. We apply the previous methodology using data from two clinical studies in psychiatry and ophthalmology. Copyright © 2005 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>16220497</pmid><doi>10.1002/sim.2315</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0277-6715
ispartof Statistics in medicine, 2006-01, Vol.25 (2), p.205-221
issn 0277-6715
1097-0258
language eng
recordid cdi_proquest_miscellaneous_67605035
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Antipsychotic Agents - therapeutic use
Biomarkers
Clinical trials
Correlation analysis
Data Interpretation, Statistical
hierarchical model
Humans
Interferon-alpha - therapeutic use
likelihood reduction factor
Longitudinal Studies
Macular Degeneration - drug therapy
Medical research
Meta-Analysis as Topic
Predictive Value of Tests
Prentice criteria
Randomized Controlled Trials as Topic - methods
Reproducibility of Results
Risperidone - therapeutic use
Schizophrenia - drug therapy
Statistical analysis
surrogate endpoints
Validation studies
Visual Acuity - drug effects
title A unifying approach for surrogate marker validation based on Prentice's criteria
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A53%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20unifying%20approach%20for%20surrogate%20marker%20validation%20based%20on%20Prentice's%20criteria&rft.jtitle=Statistics%20in%20medicine&rft.au=Alonso,%20Ariel&rft.date=2006-01-30&rft.volume=25&rft.issue=2&rft.spage=205&rft.epage=221&rft.pages=205-221&rft.issn=0277-6715&rft.eissn=1097-0258&rft.coden=SMEDDA&rft_id=info:doi/10.1002/sim.2315&rft_dat=%3Cproquest_cross%3E972308431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223140339&rft_id=info:pmid/16220497&rfr_iscdi=true